Insulin-like Growth Factor I and its binding protein 3 in sepsis

Growth Hormone and IGF Research

Volumn 23, Issue 4, 2013, Pages 98-104

  Papastathi, Chrysoula ^a   Mavrommatis, Antonis ^b   Mentzelopoulos, Spyros ^a   Konstandelou, Evangellia ^b   Alevizaki, Maria ^a   Zakynthinos, Spyros ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b GENERAL HOSPITAL OF NIKEA   (Greece)

Author keywords

Albumin; Cortisol; GH IGF I axis; Growth hormone; Insulin; Insulin like Growth Factor Binding Protein 3; Insulin like Growth Factor I; Sepsis; Septic shock; Severe sepsis

Indexed keywords

ALBUMIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; GROWTH HORMONE; HYDROCORTISONE; INSULIN; INTERLEUKIN 6; LIOTHYRONINE; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; THYROXINE;

ACUTE DISEASE; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; ENDOCRINE DISEASE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN PROTEIN INTERACTION; SEPSIS; SEPTIC SHOCK; THYROID FUNCTION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMAN GROWTH HORMONE; HUMANS; HYDROCORTISONE; INSULIN; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; INTERLEUKIN-6; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; SEPSIS; THYROXINE; YOUNG ADULT;

EID: 84878649166     PISSN: 10966374     EISSN: 15322238     Source Type: Journal    
DOI: 10.1016/j.ghir.2013.03.005     Document Type: Article

References (48)

1. Hawker F.H., Stewart P.M., Baxter R.C., Borkmann M., Tan K., Caterson I.D., McWilliam D.B. Relationship of somatomedin insulin-like growth factor-I levels to conventional nutritional indices in critically ill patients. Crit. Care Med. 1987, 15:732-736.
2. Ross R.J.M., Miell J.P., Freeman E., Jones J., Matthews D., Prece M., Buchanan C. Critically ill patients have high basal growth hormone levels with attenuated oscillatory activity associated with low levels of insulin-like growth factor-I. Clin. Endocrinol. (Oxf.) 1991, 35:47-54.
3. Voerman H.J., Strack van Schijndel R.J., Johan Groeneveld A.B., de Boer H., Nauta J.P., van der Veen E.A., Thijs L.G. Effects of recombinant human growth hormone in patients with severe sepsis. Ann. Surg. 1992, 216:648-655.
4. Voerman H.J., Strack van Schijndel R.J., Johan Groeneveld A.B., de Boer H., Nauta J.P., Thijs L.G. Effects of human GH in critically ill nonseptic patients: results from a prospective, randomised, placebo-controlled trial. Crit. Care Med. 1995, 23:665-673.
5. Saito H., Inoue T., Fukatsu K., Ming-Tsan L., Inaba T., Fukushima R., Muto T. Growth hormone and the immune response to bacterial infection. Horm. Res. 1996, 45:50-54.
6. Timmins A.C., Cotterill A.M., Hughes Cwyfan C., Holly J.M.P., Ross R.J.M., Blum W., Hinds C.J. Critical illness is associated with low circulating concentrations of insulin-like growth factors-I and -II alterations in insulin-like growth factor binding proteins, and induction of an insulin-like growth factor binding protein 3 protease. Crit. Care Med. 1996, 24:1460-1466.
7. Yarwood G.D., Ross R.J.M., Medbak S., Coakley J., Hinds C.J. Administration of human recombinant insulin-like growth factor I in critically ill patients. Crit. Care Med. 1997, 25:55-62.
8. Bjarnason R., Wickelgren R., Hermansson M., Hammarqvist F., Carlsson B.J., Carlsson L. Growth hormone treatment prevents the decrease in IGF-I gene expression in patients undergoing abdominal surgery. J. Clin. Endocrinol. Metab. 1998, 83:1566-1572.
9. Takala J., Ruokonen E., Webster N.R., Nielsen M.S., Zandstra D.F., Vundelinck G., Hinds C.J. Increased mortality associated with growth hormone treatment in critically ill patients. N. Engl. J. Med. 1999, 341:785-792.
10. Van den Berghe G. Endocrine changes in critically ill patients. Growth Horm. IGF Res. 1999, 9:77-81.
11. Jackson N.C., Carroll P.V., Russell-Jones D.L., Sonken P.H., Treacher D.F., Umpleby A.M. Effects of glutamine supplementation, GH, and IGF-I on glutamine metabolism in critically ill patients. Am. J. Physiol. Endocrinol. Metab. 2000, 278:E226-E233.
12. Ruokonen E., Takala J. Dangers of growth hormone therapy in critically ill patients. Curr. Opin. Clin. Nutr. Metab. Care 2002, 5:199-209.
13. Van den Berghe G., De Zegher F., Bouillon R. Acute and prolonged critical illness as different neuroendocrine paradigms. J. Clin. Endocrinol. Metab. 1998, 83:1827-1834.
14. Pittoni G., Gallioi G., Zanello M., Gianotti L., Boghen M.F., Colombo S., et al. Activity of GH/IGF-I axis in trauma and septic patients during artificial nutrition: different behaviour patterns?. J. Endocrinol. Investig. 2002, 25:214-222.
15. Frayn K.N., Price D.A., Maycock P.F., Carroll S.M. Plasma somatomedin activity after injury in man and its relationship to other hormonal and metabolic changes. Clin. Endocrinol. (Oxf.) 1984, 20:179-187.
16. Gianotti L., Broglio F., Aimaretti G., Arvat E., Colombo S., Di Summa M., et al. Low IGF-I levels are often uncoupled with elevated GH level in catabolic conditions. J. Endocrinol. Investig. 1998, 21:115-121.
17. Russell J.A. Management of sepsis. N. Engl. J. Med. 2006, 355:1699-1713.
18. Defalque D., Brandt N., Ketelslegrs J.M., Thissen J.P. GH insensitivity induced by endotoxin injection is associated with decreased liver GH receptors. Am. J. Physiol. 1999, 276:565-572.
19. Wang P., Li Ning, Li Jie-Shou, Li Wei-Qin The role of endotoxin, TNF-a and IL-6 in inducing the state of growth hormone insensitivity. World J. Gastroenterol. 2002, 8:531-536.
20. Lang C.H., Fan J., Wojnar M.M., Vary T.C., Cooney R. Role of central IL-1 in regulating IGF I during endotoxemia and sepsis. Am. J. Physiol. 1998, 274:956-962.
21. Briand N., Dadoun F., Pommier G., Sauze N., Lebouc Y., Oliver C., Dutour A. IGF-I/IGFBPs system response to endotoxin challenge in sheep. J. Endocrinol. 2000, 164:361-369.
22. Lang C.H., Pollard V., Fan J., Traber L.D., Gelato M.C. Acute alterations in growth hormone-insulin-like growth factor axis in humans injected with endotoxin. Am. J. Physiol. 1997, 273:371-378.
23. Schuetz P., Muller B., Nusbaume C.H., Wieland M., Christ-Crain M. Circulating levels of GH predict mortality and complement prognostic scores in critically ill medical patients. Eur. J. Endocrinol. 2009, 160:157-163.
24. De Groof F., Joosten K.F.M., Janssen J.A.M.J.L., De Kleijn E.D., Hazelzet J.A., Hop W.C.J., Uitterlinden P., Van Doorn J., Hooken-Koelega A.C.S. Acute stress response in children with meningococcal sepsis: important differences in the growth hormone/insulin-like growth factor I axis between nonsurvivors and survivors. J. Clin. Endocrinol. Metab. 2002, 87:3118-3124.
25. Marquardt D.J., Knatz N.L., Wetterau L.A., Wewers M.D., Hall M.W. Failure to recover somatotropic axis function is associated with mortality from pediatric sepsis-induced multiple organ dysfunction syndrome. Crit. Care Med. 2010, 11:18-22.
26. American College of Chest Physicians/Society of Critical Care Medicine consensus conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit. Care Med. 1992, 20:864-874.
27. Marshall J.C., Cook D.J., Christou N.V., Bernard G.B., Sprung C.L., Sibbald W.J. Multiple Organ Dysfunction Score. A reliable descriptor of a complex clinical outcome. Crit. Care Med. 1995, 23:1638-1652.
28. Knaus W.A., Draper E.A., Wanger D., Zimmerman J.E. APACHE II: a severity of disease classification system. Crit. Care Med. 1985, 13:818-882.
29. Vincent J.-L., de Mondonca A., Cantraine F., Moreno R., Takala J., Suter P.M., Sprung C.L., Colardyn F., Blecher S. Use of SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Crit. Care Med. 1998, 26:1793-1800.
30. Hanley J.A., McNeil B.J. The meaning and use of the area under the receiver operating characteristic (ROC) curve. Radiology 1982, 143:29-36.
31. Van deb Berghe G., de Zegher F., Baxter R.C. On the neuroendocrinology of prolonged critical illness: effect of continuous thyrotropin-releasing hormone infusion and its combination with growth-hormone secretagogues. J. Clin. Endocrinol. Metab. 1998, 83:309-319.
32. Guistina A., Veldhuis J.D. Pathophysiology of the neuroregulation of GH secretion in experimental animals and the human. Endocr. Rev. 1998, 19:717-797.
33. Chen Yu, Sun Difei, Vidya M., Krishnamurthy R., Rabkin R. Endotoxin attenuates GH induced hepatic IGF I expression by inhibiting JAK2/STAT 5 signal transduction and STAT5b DNA binding. Am. J. Physiol. Endocrinol. Metab. 2007, 292:1856-1862.
34. Wang P., Li N., Li J.S., Li W.Q. The role of endotoxin, TNF-α, and IL-6 in inducing the state of growth hormone insensitivity. World J. Gastroenterol. 2002, 8:531-536.
35. Joosten K.F., de Kleijn E.D., Westerterp M., de Hoog M., Eijck F.C., Hop W.C.J. Endocrine and metabolic responses in children with meningoccocal sepsis: striking differences between survivors and non survivors. J. Clin. Endocrinol. Metab. 2000, 85:3746-3753.
36. Bondanell M., Zatelli M.C., Ambrosio M.R., degli Umberti E.C. Systemic illness. Pituitary 2008, 11:187-207.
37. Firth S.M., Baxter R.C. Cellular actions of the insulin-like growth factor binding proteins. Endocr. Rev. 2002, 23:824-854.
38. Houang M., Cabrol S., Perin L., Ducos B., Bensman A., Le Bouc Y. Insulin-like growth factor-I (IGF-I), insulin-like growth factor binding proteins (IGFBP) and insulin-like growth factor type I receptor in children with various status of chronic renal failure. Growth Horm. IGF Res. 2000, 10:332-341.
39. Reinehr T., Panteliadou A., de Sousa G., Andler W. Insulin-like growth factor-I, insulin-like growth factor binding protein-3 and growth in obese children before and after reduction of overweight. J. Pediatr. Endocrinol. Metab. 2009, 22:225-233.
40. Camacho-Hubner C., Busby W.H., McCusker R.H., Wright G., Clemmons D.R. Identification of the forms of insulin-like growth factor binding proteins produced by human fibroblasts and the mechanisms that regulate their secretion. J. Biol. Chem. 1992, 267:11949-11956.
41. Tamion F. Albumine dans les etats infectieux graves. Ann. Fr. Anesth. Reanim. 2010, 29:629-634.
42. Ballmer P.E. Causes and mechanisms of hypoalbuminemia. Clin. Nutr. 2001, 20:271-273.
43. Holland P.C., Hancock S.W., Hodge D., Thompson D., Shires S., Evans S. Degradation of albumin in meningococcal sepsis. Lancet 2001, 357:2102-2104.
44. Vincent J.-L., Dubois M.J., Navickis R.J., Wilkes M.M. Hypoalbuminemia in acute illness: is there a rationale for intervention? A meta-analysis of cohort studies and controlled trials. Ann. Surg. 2003, 237:319-334.
45. Conchillo M., de Knegt R.J., Payeras M., Quiroga J., Sangro B., Herrero J.I., Castilla-Cortazar I., Frystyk J., Flyvbjerg A., Yoshizawa C., Jansen P.L., Scharschmidt B., Prieto J. Insulin-like growth factor I (IGF-I) replacement therapy increases albumin concentration in liver cirrhosis: results of a pilot randomized controlled clinical trial. J. Hepatol. 2005, 43:630-636.
46. Agha A., Monson J.P. Modulation of glucocorticoid metabolism by the growth hormone-IGF-1 axis. Clin. Endocrinol. 2007, 66:459-465.
47. Tschop M., Lahner H., Feldmeier H., Grasberger H., Morrison K.M., Janssen O.E., Attanasio A.F., Strasburger C.J. Effects of growth hormone replacement therapy on levels of cortisol and cortisol-binding globulin in hypopituitary adults. Eur. J. Endocrinol. 2000, 143:769-773.
48. Li Y.H., Fan J., Lang C.H. Differential role of glucocorticoids in mediating endotoxin-induced changes in IGF-I and IGFBP-1. Am. J. Physiol. 1997, 272:1990-1997.